LIXT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Lixte Biotechnology Holdings Inc | Needs refresh | Last updated: 2026-04-23T10:26:17Z

TickerLIXT

Market Cap44.5M

Cash RunwayRunway 6-12 months

Next CatalystData Readout

Public Research Snapshot

Lixte Biotechnology Holdings Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for LB-100 for Injection in Tumors | Neoplasms | Cancer (Phase 1).

Pipeline

Asset	Indication	Modality	Stage	Public Note
LB-100	Myelodysplastic Syndromes	n/a	Preclinical	Public pipeline row
LB-100 for Injection	Tumors \| Neoplasms \| Cancer	n/a	Phase 1	Public pipeline row

Catalyst Preview

Catalyst	Timing	Asset	Confidence
Data Readout	Timing not specified	n/a	Low
Corporate Update	Timing not specified	n/a	Low
Corporate Update	Timing not specified	LB-100	Low

Cash Runway Preview

Estimated cash runway: Runway 6-12 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT01837667	Phase 1	COMPLETED	29	2016-09
NCT03886662	Phase 1 \| Phase 2	RECRUITING	47	2021-05

Scientific Context

catalyst_type | Data Readout
catalyst_type | Data Readout
catalyst_type | Corporate Update
catalyst_type | Data Readout
catalyst_type | Corporate Update

Want the full LIXT research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.